Consensus Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
27.27 ^USD	-2.19%		-2.92%	-2.92%

May. 16	Transcript : Royalty Pharma plc Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
May. 14	Transcript : Royalty Pharma plc Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 09:00 AM

Evolution of the average Target Price on Royalty Pharma plc

Price target over the last 5 years

History of analyst recommendation changes

38c911d6d57a1c5746b82cbb2b09.u78bq2rM1zbBqLjChW8IvHpj4R3QfcCOehgkFFPabtA.3NdE9BKi-lTw7PqA7x4l3h061FS_KY74HHtGYBCDJLX89W3oC5WWbojg9Q~8790b207a30aed951b07580615bddf21

Analyst Recommendations on Royalty Pharma plc

Morgan Stanley Lifts Price Target on Royalty Pharma to $46 From $44, Keeps Overweight Rating	Apr. 09	MT
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating	Feb. 20	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $50 From $56, Keeps Buy Rating	Feb. 20	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $46 From $57, Keeps Overweight Rating	Dec. 12	MT
ANALYST RECOMMENDATIONS : Adobe, Amgen, Blackrock, IBM, Ulta Beauty...	Dec. 12
Morgan Stanley Adjusts Price Target on Royalty Pharma to $57 From $54, Maintains Overweight Rating	Nov. 09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $53, Maintains Overweight Rating	23-10-11	MT
UBS Adjusts Royalty Pharma Price Target to $41 From $44, Maintains Buy Rating	23-08-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $53 From $52, Maintains Overweight Rating	23-08-09	MT
UBS Adjusts Royalty Pharma Price Target to $44 From $48, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $52 From $50, Maintains Overweight Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $50 From $48, Maintains Overweight Rating	23-04-10	MT
Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	23-04-04	AQ
Bank of England lifts rates by 25 basis points	23-03-23	AN
UBS Adjusts Royalty Pharma's Price Target to $48 From $51, Maintains Buy Rating	23-02-16	MT
Morgan Stanley Cuts Price Target on Royalty Pharma to $51 From $54, Maintains Overweight Rating	22-12-06	MT
UBS Adjusts Royalty Pharma Price Target to $51 From $50, Maintains Buy Rating	22-11-09	MT
Morgan Stanley Adjusts Price Target on Royalty Pharma to $54 From $51, Maintains Overweight Rating	22-11-09	MT
JPMorgan Chase Adjusts Royalty Pharma's Price Target to $52 From $50, Keeps Overweight Rating	22-10-18	MT
Morgan Stanley Increases Royalty Pharma's Price Target to $51 From $48, Maintains Overweight Rating	22-08-08	MT
Goldman Sachs Adjusts Price Target for Royalty Pharma to $56 From $55, Maintains Buy Rating	22-08-05	MT
Citigroup Adjusts Price Target on Royalty Pharma to $60 From $50, Reiterates Buy Rating	22-07-29	MT
Goldman Sachs Cuts Price Target on Royalty Pharma to $55 From $57, Maintains Buy Rating	22-07-28	MT
Tigress Financial Adjusts Royalty Pharma's Price Target to $57 From $52, Maintains Buy Rating	22-07-14	MT
UBS Raises Royalty Pharma's Price Target to $50 From $47, Buy Rating Maintained	22-07-12	MT